ELI LILLY AND COMPANY Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties
ELI LILLY AND COMPANY (LLY) reported Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties · last filed 2014-02-19
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for the quarter ending 2013-12-31 was $0.00.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for the quarter ending 2012-12-31 was $0.00.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for the quarter ending 2012-09-30 was $165.00M.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for the quarter ending 2011-12-31 was $0.00.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for fiscal 2012 was $165.00M.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for fiscal 2011 was -$165.00M.
- ELI LILLY AND COMPANY proceeds from collection of (payments to fund) long-term loans to related parties for fiscal 2010 was $0.00.
| Period end | Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties 3 month | Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties 6 month | Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties 9 month | Proceeds from Collection of (Payments to Fund) Long-term Loans to Related Parties 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $0.00 10-K · filed 2014-02-19 | ||
| 2013-09-30 | $0.00 10-Q · filed 2013-10-30 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $165.00M derived: sum of 2 quarters · filed 2014-02-19 | $165.00M 10-K · filed 2014-02-19 | |
| 2012-09-30 | $165.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $165.00M 10-Q · filed 2013-10-30 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-07-27 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $0.00 derived: sum of 2 quarters · filed 2014-02-19 | -$165.00M 10-K · filed 2014-02-19 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | -$165.00M 10-Q · filed 2012-10-26 | ||
| 2011-06-30 | -$165.00M 10-Q · filed 2012-07-27 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $0.00 derived: sum of 2 quarters · filed 2013-02-21 | $0.00 10-K · filed 2013-02-21 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $0.00 10-Q · filed 2011-10-28 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-07-29 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |